SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Nordmark Gunnel) "

Sökning: WFRF:(Nordmark Gunnel)

  • Resultat 1-10 av 159
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Duker, Elisabeth, et al. (författare)
  • The use of CMC as a dry strength agent - the interplay between CMC attachment and drying.
  • 2008
  • Ingår i: Nordic Pulp & Paper Research Journal. - : Walter de Gruyter GmbH. - 0283-2631 .- 2000-0669. ; 23:1, s. 65-71
  • Tidskriftsartikel (refereegranskat)abstract
    • This paper deals with the ability to use high molecular weight CMC as a dry strength agent in paper and how the drying of the pulp, either before or after the CMC attachment, affects the mechanical properties of the paper. The effect of the counter-ion form used during drying and reslushing was also investigated. In the case of the calcium and hydrogen counter-ion forms, drying after CMC attachment had no impact on the attached amount. The sodium form did, however, result in some detachment of CMC. When the pulp was dried prior to CMC treatment, the counter-ion form had no effect on the attached amount. It was also shown that drying of a CMC-treated pulp reduced the positive effect of CMC on the mechanical properties. Nevertheless, the mechanical properties were still better than those of paper made from the never-dried reference pulp. The relative effect of CMC on the mechanical properties was independent of the drying strategy used and the counter-ion form did not affect the mechanical properties. However, surface carboxymethylation prior to drying resulted in sheets with better final mechanical properties than sheets made from pulp that had first been dried and then surface carboxymethylated.
  •  
2.
  • Acar-Denizli, N., et al. (författare)
  • Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies
  • 2020
  • Ingår i: Clinical and Experimental Rheumatology. - : CLINICAL & EXPER RHEUMATOLOGY. - 0392-856X .- 1593-098X. ; 38:4; Suppl. 126, s. S85-S94
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: To evaluate the systemic phenotype associated with the presence of isolated anti-La/SSB antibodies in a large international registry of patients with primary Sjogren's syndrome (pSS) fulfilling the 2002 classification criteria.Methods: The Big Data Sjogren Project Consortium is an international, multicentre registry created in 2014. Baseline clinical information from leading centres on clinical research in SS of the 5 continents was collected. Combination patterns of anti-Ro/SSA-La/SSB antibodies at the time of diagnosis defined the following four immunological phenotypes: double positive (combined Ro/SSA and La/SSB,) isolated anti-Ro/SSA, isolated anti-La/SSB, and immunonegative.Results: The cohort included 12,084 patients (11,293 females, mean 52.4 years) with recorded ESSDAI scores available. Among them, 279 (2.3%) had isolated anti-La/SSB antibodies. The mean total ESSDAI score at diagnosis of patients with pSS carrying isolated anti-La/SSB was 6.0, and 80.4% of patients had systemic activity (global ESSDAI score >= 1) at diagnosis. The domains with the highest frequency of active patients were the biological (42.8%), glandular (36.8%) and articular (31.2%) domains. Patients with isolated anti-La/ SSB showed a higher frequency of active patients in all ESSDAI domains but two (articular and peripheral nerve) in comparison with immune-negative patients, and even a higher absolute frequency in six clinical ESSDAI domains in comparison with patients with isolated anti-Ro/SSA. In addition, patients with isolated anti-La/SSB showed a higher frequency of active patients in two ESSDAI domains (pulmonary and glandular) with respect to the most active immunological subset (double-positive antibodies). Meanwhile, systemic activity detected in patients with isolated anti-La/SSB was overwhelmingly low. Even in ESSDAI domains where patients with isolated anti-La/SSB had the highest frequencies of systemic activity (lymphadenopathy and muscular), the percentage of patients with moderate or high activity was lower in comparison with the combined Ro/SSA and La/SSB group.Conclusion: Patients carrying isolated La/SSB antibodies represent a very small subset of patients with a systemic SS phenotype characterised by a significant frequency of active patients in most clinical ESSDAI domains but with a relative low frequency of the highest severe organ-specific involvements. Primary SS still remains the best clinical diagnosis for this subset of patients.
  •  
3.
  • Appel, Silke, et al. (författare)
  • Potential association of muscarinic receptor 3 gene variants with primary Sjogren's syndrome
  • 2011
  • Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 70:7, s. 1327-1329
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Primary Sjögren's syndrome (pSS) is characterised by a chronic inflammation of exocrine glands. Salivary gland infiltrates, however, do not correlate well with disease symptoms, and a primary role for the salivary gland parenchyma in disease development has been suggested. Specifically, dysfunction of exocrine pathways involving the muscarinic receptor 3 (CHRM3) has been indicated. Objective: To investigate possible genetic divergence in the CHRM3 gene in patients with pSS. Methods: 530 patients with pSS and 532 controls from a combined Swedish and Norwegian cohort were genotyped for 84 single nucleotide polymorphisms (SNPs) distributed throughout CHRM3. Results: Genetic association was observed with five SNPs localised in intron 3 and 4 of CHRM3, the strongest being rs7548522 (minor allele frequency = 0.06, OR=1.93, 95% CI (1.24 to 3.01); p=0.0033). In addition, clinical parameters, including focus score, abnormal Schirmer's test and presence of autoantibodies, were associated with different SNPs in CHRM3. Conclusion: The study demonstrates a novel association of CHRM3 polymorphisms with pSS, suggesting a functional role for CHRM3 and the salivary gland parenchyma in the pathogenesis of pSS.
  •  
4.
  •  
5.
  • Arvidsson, Gustav, et al. (författare)
  • Multimodal Single-Cell Sequencing of B Cells in Primary Sjögren's Syndrome
  • 2024
  • Ingår i: Arthritis & Rheumatology. - 2326-5191 .- 2326-5205. ; 76:2, s. 255-267
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective. B cells are important in the pathogenesis of primary Sjögren's syndrome (pSS). Patients positive for Sjögren's syndrome antigen A/Sjögren syndrome antigen B (SSA/SSB) autoantibodies are more prone to systemic disease manifestations and adverse outcomes. We aimed to determine the role of B cell composition, gene expression, and B cell receptor usage in pSS subgroups stratified for SSA/SSB antibodies.Methods. Over 230,000 B cells were isolated from peripheral blood of patients with pSS (n = 6 SSA−, n = 8 SSA+ single positive and n = 10 SSA/SSB+ double positive) and four healthy controls and processed for single-cell RNA sequencing (scRNA-seq) and single-cell variable, diversity, and joining (VDJ) gene sequencing (scVDJ-seq).Results. We show that SSA/SSB+ patients present the highest and lowest proportion of naïve and memory B cells, respectively, and the highest up-regulation of interferon-induced genes across all B cell subtypes. Differential usage of IGHV showed that IGHV1-69 and IGHV4-30-4 were more often used in all pSS subgroups compared with controls. Memory B cells from SSA/SSB+ patients displayed a higher proportion of cells with unmutated VDJ transcripts compared with other pSS patient groups and controls, indicating altered somatic hypermutation processes. Comparison with previous studies revealed heterogeneous clonotype pools, with little overlap in CDR3 sequences. Joint analysis using scRNA-seq and scVDJ-seq data allowed unsupervised stratification of patients with pSS and identified novel parameters that correlated to disease manifestations and antibody status.Conclusion. We describe heterogeneity and molecular characteristics in B cells from patients with pSS, providing clues to intrinsic differences in B cells that affect the phenotype and outcome and allowing stratification of patients with pSS at improved resolution.
  •  
6.
  • Berry, Joe Scott, et al. (författare)
  • Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome : proteomic and network analysis
  • 2024
  • Ingår i: Annals of the Rheumatic Diseases. - : BMJ Publishing Group Ltd. - 0003-4967 .- 1468-2060. ; 83:1, s. 88-95
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: Stratification approaches are vital to address clinical heterogeneity in Sjogren's syndrome (SS). We previously described that the Newcastle Sjogren's Stratification Tool (NSST) identified four distinct clinical subtypes of SS. We performed proteomic and network analysis to analyse the underlying pathobiology and highlight potential therapeutic targets for different SS subtypes.Method: We profiled serum proteins using O-link technology of 180 SS subjects. We used 5 O-link proteomics panels which included a total of 454 unique proteins. Network reconstruction was performed using the ARACNE algorithm, with differential expression estimates overlaid on these networks to reveal the key subnetworks of differential expression. Furthermore, data from a phase III trial of tocilizumab in SS were reanalysed by stratifying patients at baseline using NSST.Results: Our analysis highlights differential expression of chemokines, cytokines and the major autoantigen TRIM21 between the SS subtypes. Furthermore, we observe differential expression of several transcription factors associated with energy metabolism and redox balance namely APE1/Ref-1, FOXO1, TIGAR and BACH1. The differentially expressed proteins were inter-related in our network analysis, supporting the concept that distinct molecular networks underlie the clinical subtypes of SS. Stratification of patients at baseline using NSST revealed improvement of fatigue score only in the subtype expressing the highest levels of serum IL-6.Conclusions: Our data provide clues to the pathways contributing to the glandular and non-glandular manifestations of SS and to potential therapeutic targets for different SS subtypes. In addition, our analysis highlights the need for further exploration of altered metabolism and mitochondrial dysfunction in the context of SS subtypes.
  •  
7.
  •  
8.
  • Björk, Albin, et al. (författare)
  • Protein and DNA methylation-based scores as surrogate markers for interferon system activation in patients with primary Sjögren's syndrome
  • 2020
  • Ingår i: RMD Open. - : BMJ PUBLISHING GROUP. - 2056-5933. ; 6:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: Standard assessment of interferon (IFN) system activity in systemic rheumatic diseases depends on the availability of RNA samples. In this study, we describe and evaluate alternative methods using plasma, serum and DNA samples, exemplified in the IFN-driven disease primary Sjogren's syndrome (pSS).Methods: Patients with pSS seropositive or negative for anti-SSA/SSB and controls were included. Protein-based IFN (pIFN) scores were calculated from levels of PD-1, CXCL9 and CXCL10. DNA methylation-based (DNAm) IFN scores were calculated from DNAm levels at RSAD2, IFIT1 and IFI44L. Scores were compared with mRNA-based IFN scores measured by quantitative PCR (qPCR), Nanostring or RNA sequencing (RNAseq).Results: mRNA-based IFN scores displayed strong correlations between B cells and monocytes (r=0.93 and 0.95, p<0.0001) and between qPCR and Nanostring measurements (r=0.92 and 0.92, p<0.0001). The pIFN score in plasma and serum was higher in patients compared with controls (p<0.0001) and correlated well with mRNA-based IFN scores (r=0.62-0.79, p<0.0001), as well as with each other (r=0.94, p<0.0001). Concordance of classification as 'high' or 'low' IFN signature between the pIFN score and mRNA-based IFN scores ranged from 79.5% to 88.6%, and the pIFN score was effective at classifying patients and controls (area under the curve, AUC=0.89-0.93, p<0.0001). The DNAm IFN score showed strong correlation to the RNAseq IFN score (r=0.84, p<0.0001) and performed well in classifying patients and controls (AUC=0.96, p<0.0001).Conclusions: We describe novel methods of assessing IFN system activity in plasma, serum or DNA samples, which may prove particularly valuable in studies where RNA samples are not available.
  •  
9.
  • Bolin, Karin, et al. (författare)
  • Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis
  • 2013
  • Ingår i: PLOS ONE. - : Public Library of Science. - 1932-6203. ; 8:12, s. 84450-
  • Tidskriftsartikel (refereegranskat)abstract
    • Lupus nephritis is a cause of significant morbidity in systemic lupus erythematosus (SLE) and its genetic background has not been completely clarified. The aim of this investigation was to analyze single nucleotide polymorphisms (SNPs) for association with lupus nephritis, its severe form proliferative nephritis and renal outcome, in two Swedish cohorts. Cohort I (n = 567 SLE cases, n = 512 controls) was previously genotyped for 5676 SNPs and cohort II (n = 145 SLE cases, n = 619 controls) was genotyped for SNPs in STAT4, IRF5, TNIP1 and BLK. Case-control and case-only association analyses for patients with lupus nephritis, proliferative nephritis and severe renal insufficiency were performed. In the case-control analysis of cohort I, four highly linked SNPs in STAT4 were associated with lupus nephritis with genome wide significance with p = 3.7x10(-9), OR 2.20 for the best SNP rs11889341. Strong signals of association between IRF5 and an HLA-DR3 SNP marker were also detected in the lupus nephritis case versus healthy control analysis (pless than0.0001). An additional six genes showed an association with lupus nephritis with pless than0.001 (PMS2, TNIP1, CARD11, ITGAM, BLK and IRAK1). In the case-only meta-analysis of the two cohorts, the STAT4 SNP rs7582694 was associated with severe renal insufficiency with p = 1.6x10(-3) and OR 2.22. We conclude that genetic variations in STAT4 predispose to lupus nephritis and a worse outcome with severe renal insufficiency.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 159
Typ av publikation
tidskriftsartikel (134)
konferensbidrag (13)
doktorsavhandling (5)
annan publikation (4)
forskningsöversikt (3)
Typ av innehåll
refereegranskat (93)
övrigt vetenskapligt/konstnärligt (66)
Författare/redaktör
Nordmark, Gunnel (153)
Rönnblom, Lars (76)
Wahren-Herlenius, Ma ... (45)
Eloranta, Maija-Leen ... (40)
Omdal, Roald (38)
Eriksson, Per (37)
visa fler...
Jonsson, Roland (35)
Sandling, Johanna K. (34)
Imgenberg-Kreuz, Jul ... (29)
Mandl, Thomas (26)
Gunnarsson, Iva (25)
Theander, Elke (25)
Syvänen, Ann-Christi ... (25)
Svenungsson, Elisabe ... (23)
Wahren-Herlenius, M (22)
Jönsen, Andreas (21)
Mariette, Xavier (21)
Rischmueller, M. (19)
Ng, Wan-Fai (17)
Kvarnstrom, Marika (17)
Rasmussen, A (16)
Kvarnstrom, M. (16)
Mariette, X (16)
Rantapää-Dahlqvist, ... (16)
Brun, Johan G. (16)
Vasaitis, Lilian (16)
Sturfelt, Gunnar (15)
Hernandez-Molina, G. (15)
Praprotnik, S. (15)
Retamozo, S. (15)
Baldini, C. (15)
Valim, V. (15)
Giacomelli, R. (15)
Atzeni, F. (15)
Ramos-Casals, M. (15)
Brito-Zeron, P. (15)
Padyukov, Leonid (15)
Suzuki, Y. (14)
Leonard, Dag, 1975- (14)
Priori, R. (14)
Forsblad-d'Elia, Hel ... (14)
Rasmussen, Astrid (14)
Jonsson, R (13)
Acar-Denizli, N. (13)
Solans, R. (13)
Hofauer, B. (13)
Quartuccio, L (13)
Syvänen, Ann-Christi ... (13)
Gottenberg, Jacques- ... (13)
Hammenfors, D (13)
visa färre...
Lärosäte
Uppsala universitet (150)
Karolinska Institutet (101)
Lunds universitet (45)
Linköpings universitet (35)
Umeå universitet (29)
Göteborgs universitet (7)
visa fler...
Sveriges Lantbruksuniversitet (5)
Kungliga Tekniska Högskolan (3)
Örebro universitet (2)
Stockholms universitet (1)
Malmö universitet (1)
RISE (1)
visa färre...
Språk
Engelska (157)
Odefinierat språk (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (134)
Naturvetenskap (5)
Teknik (1)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy